Every DEF 14A that AEON Biopharma, Inc. (AEON) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AEON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEON filings page.
AEON Biopharma, Inc. asks stockholders to authorize the Board to effect one reverse stock split of its Class A common stock at a ratio from 1-for-2 through 1-for-100, selected by the Board during the 12 months following approval and subject to the Compliance Condition; the Board may abandon the split. Approval would not itself implement a split. AEON’s prior 1-for-72 split took effect February 26, 2025, and the exchange’s cumulative-ratio limit may constrain a new ratio while that split remains within the lookback period.
If approved, amendments to the 2023 Incentive Award Plan and ESPP would include shares underlying outstanding pre-funded warrants in the fully-diluted denominator for annual increases beginning January 1, 2027, while other warrants remain excluded. The annual increase limits remain 5% for the Plan and 1% for the ESPP, subject to smaller amounts set by the Board; neither amendment adds a fixed share reserve immediately. As of October 23, 2026, 59,084,675 Common Stock shares were outstanding and entitled to one vote each. The meeting is December 15, 2026, and the Board recommends voting FOR all four proposals.
AEON Biopharma, Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 17, 2026 at 10:00 a.m. Pacific Time at its Irvine, California offices. Holders of Class A Common Stock at the close of business on April 21, 2026, when 26,307,211 shares were outstanding, may vote in person or by proxy.
Stockholders are being asked to elect Class III directors Marc Forth and Seongsoo Park to terms running to the 2029 annual meeting, and to ratify KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy statement also details board structure, committee assignments, governance policies, and 2025 compensation for key executives, including new CEO Robert Bancroft, Chief Medical Officer Chad Oh, and Chief Legal Officer Alex Wilson.
AEON Biopharma has called a Special Meeting on January 21, 2026 to seek stockholder approval for a financing and note exchange intended to fund development and potential commercialization of ABP‑450 as a biosimilar to Botox.
Stockholders are being asked to approve a PIPE financing covering 4,616,924 shares of common stock (or pre-funded warrants) plus warrants for 6,581,829 shares and additional True-Up Warrants, which together, if exercised, are expected to raise about $11.4 million. A separate proposal would approve exchanging Daewoong’s senior secured convertible notes for a new $1.5M senior secured convertible note, a warrant for 8,000,000 shares at $1.09392 per share, and an estimated 23.1 million shares or pre-funded warrants.
The proxy also seeks to increase shares under the 2023 Incentive Award Plan by 17,288,059 shares and maintain an annual share “evergreen” of up to 5% of fully diluted shares. If both the PIPE and Exchange are completed and related warrants and pre-funded instruments are exercised as illustrated, total common shares outstanding would rise to 46,459,667, with Daewoong and PIPE investors becoming the largest holders.